Incidence and predictors of in-stent restenosis following intervention for pulmonary vein stenosis due to fibrosing mediastinitis.

IF 3.4 2区 医学 Q2 GENETICS & HEREDITY
Mengfei Jia, Hongling Su, Kaiyu Jiang, Aqian Wang, Zhaoxia Guo, Hai Zhu, Fu Zhang, Xuechun Sun, Yiwei Shi, Xin Pan, Yunshan Cao
{"title":"Incidence and predictors of in-stent restenosis following intervention for pulmonary vein stenosis due to fibrosing mediastinitis.","authors":"Mengfei Jia, Hongling Su, Kaiyu Jiang, Aqian Wang, Zhaoxia Guo, Hai Zhu, Fu Zhang, Xuechun Sun, Yiwei Shi, Xin Pan, Yunshan Cao","doi":"10.1186/s13023-024-03391-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fibrosing mediastinitis (FM) is a rare yet fatal condition, caused by different triggers and frequently culminating in the obstruction of the pulmonary vasculature and airways, often leading to pulmonary hypertension and right heart failure. Percutaneous transluminal pulmonary venoplasty (PTPV) is an emerging treatment for pulmonary vein stenosis (PVS) caused by FM. Our previous study showed as high as 24% of in-stent restenosis (ISR) in FM. However, the predictors of ISR are elusive.</p><p><strong>Objectives: </strong>We sought to identify the predictors of ISR in patients with PVS caused by extraluminal compression due to FM.</p><p><strong>Methods: </strong>We retrospectively enrolled patients with PVS-FM who underwent PTPV between July 1, 2018, and December 31, 2022. According to ISR status, patients were divided into two groups: the ISR group and the non-ISR group. Baseline characteristics (demographics and lesions) and procedure-related information were abstracted from patient records and analyzed. Univariate and multivariate analyses were performed to determine the predictors of ISR.</p><p><strong>Results: </strong>A total of 142 stents were implanted in 134 PVs of 65 patients with PVS-FM. Over a median follow-up of 6.6 (3.4-15.7) months, 61 of 134 PVs suffered from ISR. Multivariate analysis demonstrated a significantly lower risk of ISR in PVs with a larger reference vessel diameter (RVD) (odds ratio (OR): 0.79; 95% confidence interval [CI]: 0.64 to 0.98; P = 0.032), and stenosis of the corresponding pulmonary artery (Cor-PA) independently increased the risk of restenosis (OR: 3.41; 95% CI: 1.31 to 8.86; P = 0.012). The cumulative ISR was 6.3%, 21.4%, and 39.2% at the 3-, 6-, and 12-month follow-up, respectively.</p><p><strong>Conclusion: </strong>ISR is very high in PVS-FM, which is independently associated with RVD and Cor-PA stenosis.</p><p><strong>Trail registration: </strong>Chinese Clinical Trials Register; No.: ChiCTR2000033153. URL: http://www.chictr.org.cn .</p>","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472477/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-024-03391-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Fibrosing mediastinitis (FM) is a rare yet fatal condition, caused by different triggers and frequently culminating in the obstruction of the pulmonary vasculature and airways, often leading to pulmonary hypertension and right heart failure. Percutaneous transluminal pulmonary venoplasty (PTPV) is an emerging treatment for pulmonary vein stenosis (PVS) caused by FM. Our previous study showed as high as 24% of in-stent restenosis (ISR) in FM. However, the predictors of ISR are elusive.

Objectives: We sought to identify the predictors of ISR in patients with PVS caused by extraluminal compression due to FM.

Methods: We retrospectively enrolled patients with PVS-FM who underwent PTPV between July 1, 2018, and December 31, 2022. According to ISR status, patients were divided into two groups: the ISR group and the non-ISR group. Baseline characteristics (demographics and lesions) and procedure-related information were abstracted from patient records and analyzed. Univariate and multivariate analyses were performed to determine the predictors of ISR.

Results: A total of 142 stents were implanted in 134 PVs of 65 patients with PVS-FM. Over a median follow-up of 6.6 (3.4-15.7) months, 61 of 134 PVs suffered from ISR. Multivariate analysis demonstrated a significantly lower risk of ISR in PVs with a larger reference vessel diameter (RVD) (odds ratio (OR): 0.79; 95% confidence interval [CI]: 0.64 to 0.98; P = 0.032), and stenosis of the corresponding pulmonary artery (Cor-PA) independently increased the risk of restenosis (OR: 3.41; 95% CI: 1.31 to 8.86; P = 0.012). The cumulative ISR was 6.3%, 21.4%, and 39.2% at the 3-, 6-, and 12-month follow-up, respectively.

Conclusion: ISR is very high in PVS-FM, which is independently associated with RVD and Cor-PA stenosis.

Trail registration: Chinese Clinical Trials Register; No.: ChiCTR2000033153. URL: http://www.chictr.org.cn .

纤维性纵隔炎导致的肺静脉狭窄介入治疗后支架内再狭窄的发生率和预测因素。
背景:纤维化纵隔炎(FM)是一种罕见但致命的疾病,由不同的诱因引起,经常导致肺血管和气道阻塞,通常会引发肺动脉高压和右心衰竭。经皮腔内肺静脉成形术(PTPV)是治疗 FM 引起的肺静脉狭窄(PVS)的一种新兴疗法。我们之前的研究显示,在 FM 患者中,支架内再狭窄(ISR)的发生率高达 24%。然而,ISR 的预测因素却难以捉摸:我们试图找出因 FM 引起的腔外压迫导致 PVS 患者 ISR 的预测因素:我们回顾性地纳入了在 2018 年 7 月 1 日至 2022 年 12 月 31 日期间接受 PTPV 的 PVS-FM 患者。根据 ISR 状态,患者被分为两组:ISR 组和非 ISR 组。从患者记录中抽取并分析了基线特征(人口统计学和病变)和手术相关信息。进行单变量和多变量分析以确定ISR的预测因素:65名PVS-FM患者的134个PV共植入了142个支架。在中位随访 6.6 (3.4-15.7) 个月期间,134 个 PV 中的 61 个发生了 ISR。多变量分析表明,参考血管直径(RVD)较大的静脉血管发生 ISR 的风险明显较低(几率比 (OR): 0.79; 95% 置信区间 [CI]:0.64至0.98;P = 0.032),而相应肺动脉(Cor-PA)的狭窄会独立增加再狭窄的风险(OR:3.41;95% CI:1.31至8.86;P = 0.012)。在3个月、6个月和12个月的随访中,累积ISR分别为6.3%、21.4%和39.2%:结论:PVS-FM的ISR非常高,与RVD和Cor-PA狭窄独立相关:试验注册:中国临床试验注册中心;编号:ChiCTR2000033153。URL: http://www.chictr.org.cn 。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases 医学-医学:研究与实验
CiteScore
6.30
自引率
8.10%
发文量
418
审稿时长
4-8 weeks
期刊介绍: Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信